KR970704476A - 이중 코팅을 갖는 철-함유 나노입자 및 진단 및 치료에 있어서의 그의 용도(Ironcontaining nanoparticles with double coating and their use in diagnosis and therapy) - Google Patents

이중 코팅을 갖는 철-함유 나노입자 및 진단 및 치료에 있어서의 그의 용도(Ironcontaining nanoparticles with double coating and their use in diagnosis and therapy) Download PDF

Info

Publication number
KR970704476A
KR970704476A KR1019970700649A KR19970700649A KR970704476A KR 970704476 A KR970704476 A KR 970704476A KR 1019970700649 A KR1019970700649 A KR 1019970700649A KR 19970700649 A KR19970700649 A KR 19970700649A KR 970704476 A KR970704476 A KR 970704476A
Authority
KR
South Korea
Prior art keywords
iron
nanoparticle
mixture
containing core
synthetic polymer
Prior art date
Application number
KR1019970700649A
Other languages
English (en)
Other versions
KR100278513B1 (ko
Inventor
크레세 마이크
프페페러 테트레프
라바첵크 뤼디거
바그너 수잔네
에버트 볼프강
엘스테 볼커
셈믈러 볼프하르트
타우피츠 마티아스
가이다 요젭
헤르만 안자
유클 모니카
스비더스키 우드
Original Assignee
셈믈러 볼프하르트
인스티튜트 피르 디아그노스티크포르슝 게엠베하 안 데르 프라이엔 유니버시태트 베를린
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셈믈러 볼프하르트, 인스티튜트 피르 디아그노스티크포르슝 게엠베하 안 데르 프라이엔 유니버시태트 베를린 filed Critical 셈믈러 볼프하르트
Publication of KR970704476A publication Critical patent/KR970704476A/ko
Application granted granted Critical
Publication of KR100278513B1 publication Critical patent/KR100278513B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
    • G01N2400/14—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar alpha-D-Glucans, i.e. having alpha 1,n (n=3,4,6) linkages between saccharide units, e.g. pullulan
    • G01N2400/22—Dextran
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/20—Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/30—Magnetic particle immunoreagent carriers the magnetic material being dispersed in the polymer composition before their conversion into particulate form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 모듈 구조를 갖는 철-함유 나노입자, 그의 제조방법 및 진단 및 치료 목적에 있어서 그의 용도에 관한 것이다.
본 발명에 따른 나노입자는 철-함유코어, 제1코트(합성중합체) 및 제2코트(표적 중합체), 및 임의로 약제학적 보조제, 약제 및/또는 흡착 매체/증강제로 구성됨을 특징으로 한다.

Description

이중 코팅을 갖는 철-함유 나노입자 및 진단 및 치료에 있어서의 그의 용도(lron-containing nanoparticles with double coating and their use in diagnosis and therapy)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (32)

  1. 철-함유 코어, 제1코트(합성 중합체) 및 제2코트(표적 중합체), 및 임의로 약제학적 보조제, 약제 및/또는 흡착 매체/증강제로 구성됨을 특징으로 하는 나노입자.
  2. 제1항에 있어서, 제1코트 및 철-함유 코어의 기본 구조 유니트의 유체역학적 직경이 용액중에서 100mm 보다 작으며, 철-함유 코어의 직경보다 5배 이상 크지 않음을 특징으로 하는 나노입자.
  3. 제1항 또는 2항에 있어서, 철-함유 코어가 마그네타이트 및/또는 마그헤마이트로 구성되거나, 또는 이들 두 성분중의 적어도 하나를 함유함을 특징으로 하는 나노입자.
  4. 제1항 내지 3항 중의 어느 하나에 있어서, 철-함유 코어중의 철 25중량% 이하가 다른 금속 이온으로 대체됨을 특징으로 하는 나노입자.
  5. 제4항에 있어서, 비-철 금속 이온이 상자성 또는 반자성이거나, 상자성 및 반자성 금속 이온의 혼합물임을 특징으로 하는 나노입자.
  6. 제1항 내지 5항 중의 어느 하나에 있어서, 철-함유 코어가 전자 현미경을 사용하여 측정한 것으로 30nm미만의 직경을 갖고, 최소 50개의 금속 이온을 함유하며, 입자 크기 분포가 적어도 90%의 철-함유 코어가 0.7×평균 내지 1.3×평균 범위에 있도록 되어 있음을 특징으로 하는 나노입자.
  7. 제1항 내지 6항 중의 어느 하나에 있어서, 존재하는 금속 이온의 총 합의 0.01배 내지 1배 양(w/w) 의 합성 중합체를 함유함을 특징으로 하는 나노입자.
  8. 제1항 내지 7항중의 어느 하나에 있어서, 합성 중합체가 모노머 또는 폴리머 물질, 또는 이들 물질 또는 유도체의 혼합물, 또는 기능 그룹을 갖는 유도체의 혼합물, 또는 부가적으로 치환된 유도체의 혼합물이며, 10,000Da 미만의 분자량을 가짐을 특징으로 하는 나노입자.
  9. 제1항 내지 8항 중의 어느 하나에 있어서, 합성 중합체가 덱스트란, 그의 유도체, 또는 덱스트란 및/ 또는 덱스트란 유도체의 혼합물임을 특징으로 하는 나노입자.
  10. 제8항 또는 9항에 있어서, 합성 중합체가 그의 분자내에 하나 또는 다수의 산 그룹, 또는 N,S,P또는 O원자를 함유하는 수개의 기능 그룹을 포함함을 특징으로 하는 나노입자.
  11. 제1항 내지 10항 중의 어느 하나에 있어서, 표적 및 합성 중합체가 동일하거나 상이한 물질 또는 이들 물질의 혼합물임을 특징으로 하는 나노입자.
  12. 제1항 내지 11항 중의 어느 하나에 있어서, 함유된 표적 중합체의 중량이 존재하는 금속 이온 중량의 0.5배 내지 50배 임을 특징으로 하는 나노입자.
  13. 제1항 내지 12항 중의 어느 하나에 있어서, 함유된 금속 이온 총 중량보다 작거나 또는 이와 동일한 양으로 흡착 매체/증강제를 함유함을 특징으로 하는 나노입자.
  14. 제13항에 있어서, 흡착 매체/증강제로서 펩타이드를 함유함을 특징으로 하는 나노입자.
  15. 제1항 내지 14항 중의 어느 하나에 있어서, 모든 성분의 유체역학적 직경이 그의 철-함유 코어의 직경의 10배를 넘지 않으며, 그의 기본 구조 유니트의 직경보다 최대 20%큼을 특징으로 하는 나노입자.
  16. 제1항 내지 15항 중의 어느 하나에 있어서, 어떤 시기에나 배합될 수 있는 기본 구조 유니트, 표적 중합체, 약제 및 흡착매체와 같은 개개 모듈로 구성됨을 특징으로 하는 나노입자.
  17. 제1단계에서 합성 중합체의 존재하에 염기 처리하여 철-함유 코어를 제조하고, 제2단계에서 탈착 방법에 의해 철 대 합성 중합체 비를 변화시키고, 제3단계에서 표적 중합체를 흡착시키고, 임의로 흡착 매체/증강제, 약제학적 보조제 및/또는 약제를 첨가함을 특징으로 하여, 제1항에 따르는 나노입자를 제조하는 방법.
  18. 제17항에 있어서, 철(Ⅱ) 및 철(Ⅲ) 염의 혼합물을 사용하여 철-함유 코어를 제조하고, 여기에서 2가대 3가 철의 비는 1 : 1내지 1:20임을 특징으로 하는 방법.
  19. 제17항 또는 18항에 있어서, 철(Ⅲ) 염 혼합물을 환원제와 함께 사용하여 철 -함유 코어를 제조하고, 철(Ⅱ) 대 철(Ⅲ) 비가 1;1 내지 1:20이 되도록 환원제의 양을 선택함을 특징으로 하는 방법.
  20. 제17항 내지 19항 중의 어느 하나에 있어서, 사용된 철 화합물이 무기 및 유기 염과 그의 착물의 혼합물임을 특징으로 하는 방법.
  21. 제17항 내지 20항 중의 어느 하나에 있어서, 철-함유 결정이 각각 제조된 수산화철(Ⅱ)및 수산화철(Ⅲ)용액을 혼합함으로써 제조됨을 특징으로 하는 방법.
  22. 제17항 내지 21항 중의 어느 하나에 있어서, 사용한 금속 이온의 25% 이하가 비-철 이온임을 특징으로 하는 방법.
  23. 제22항에 있어서, 비-철 금속 이온이 상자성 또는 반자성이거나, 상자성 및 반자성 금속 이온의 혼합물임을 특징으로 하는 방법.
  24. 제17항 내지 23항 중의 어느 하나에 있어서, 물질 또는 물질의 배합물이 상호 침전에 의해 생성된 결정을 분리하는 합성 중합체로서 사용되고, 반응 혼합물중의 합성 중합체의 양이 함유된 금속이온의 중량의 0.5내지 20배를 초과하지만 반응 혼합물의 50%(g/v) 를 초과하지 않음을 특징으로 하는 방법.
  25. 제17항 내지 24항 중의 어느 하나에 있어서, 0.1 내지 10N 염기를 사용하여 신속히 첨가되는 철 화합물을 침전시킴을 특징으로 하는 방법.
  26. 제25항에 있어서, 암모니아 기체 또는 염, 아민 또는 아민 유도체, 또는 휘발성 완충액을 사용하여 철화합물을 침전시킴을 특징으로 하는 방법.
  27. 제17항 내지 26항 중의 어느 하나에 있어서, 기본 구조 유니트가 0℃ 내지 120℃의 온도 범위에서 합성됨을 특징으로 하는 방법.
  28. 제17항 내지 27항 중의 어느 하나에 있어서, 철 대 합성 중합체의 비가 1:0.01 내지 1:1(w/w)임로 고정됨을 특징으로 하는 방법.
  29. 제17항 내지 28항 중의 어느 하나에 있어서, 첨가된 표적 중합체의 양이 표적 중합체에 대한 존재하는 금속 이온의 비가 1:0.5 내지 1:50이 되도록 선택됨을 특징으로 하는 방법.
  30. 제17항 내지 29항 중의 어느 하나에 있어서, 나노입자가 안정한 콜로이드상졸이거나 동결건조되고, 단순한 용매를 사용하여 용액으로 되돌아갈 수 있거나, 또는 기본 구조 유니트, 표적 성분 및 임의의 보조제가 적용 용액을 제조하는 특정 시간에 혼합되는 분리 용액 또는 동결건조물로서 사용될 수 있음을 특징으로 하는 방법.
  31. 제17항 내지 30항 중의 어느 하나에 있어서, 나노입자의 개개 모듈이 어떤 시기에나 배합될 수 있음을 특징으로 하는 방법.
  32. 진단시 조영제로서, 수술과 같은 의약 분야에서 가시화 표지 물질로서 및 활성제용 비히클 또는 치료용 활성제로서의 나노입자의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970700649A 1994-08-04 1995-07-10 이중 코팅을 갖는 철-함유 나노입자 및 진단 및 치료에 있어서의 그의 용도 KR100278513B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP4428851.4 1994-08-04
DE4428851A DE4428851C2 (de) 1994-08-04 1994-08-04 Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
PCT/DE1995/000924 WO1996004017A1 (de) 1994-08-04 1995-07-10 Eisen enthaltende nanopartikel mit doppeltem coating und anwendung in der diagnostik und therapie

Publications (2)

Publication Number Publication Date
KR970704476A true KR970704476A (ko) 1997-09-06
KR100278513B1 KR100278513B1 (ko) 2001-01-15

Family

ID=6525704

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970700649A KR100278513B1 (ko) 1994-08-04 1995-07-10 이중 코팅을 갖는 철-함유 나노입자 및 진단 및 치료에 있어서의 그의 용도

Country Status (13)

Country Link
US (3) US6048515A (ko)
EP (1) EP0773796A1 (ko)
JP (1) JPH10503496A (ko)
KR (1) KR100278513B1 (ko)
CN (1) CN1103604C (ko)
AU (1) AU703042B2 (ko)
CA (1) CA2195318C (ko)
DE (1) DE4428851C2 (ko)
HU (1) HUT77993A (ko)
IL (1) IL114713A (ko)
NO (1) NO314785B1 (ko)
WO (1) WO1996004017A1 (ko)
ZA (1) ZA956005B (ko)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100806669B1 (ko) * 2005-06-23 2008-02-26 김정환 나노 입자-생체 복합체
KR100809402B1 (ko) * 2007-01-29 2008-03-05 김정환 나노 입자 표지, 나노 입자 표지를 이용하는 진단 키트, 및진단 방법
KR100827292B1 (ko) * 2006-05-30 2008-05-07 애니젠 주식회사 실리콘-포함 수용성 고분자로 코팅된 나노입자 및 그의조영제로서의 용도

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
KR100502881B1 (ko) * 1996-08-05 2005-07-25 쉐링 악티엔게젤샤프트 자기 공명 단층촬영용 조영제의 제조 방법
FR2753902B1 (fr) * 1996-09-27 1999-04-02 Ioualalen Karim Nouveau type de matrice ionique biodegradable de polarite interne modulable a polymere greffe
DE19652374A1 (de) * 1996-12-04 1998-06-10 Schering Ag Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
WO1998037826A1 (de) * 1997-02-26 1998-09-03 Aesculap Meditec Gmbh Marker zur bestimmung seiner position in einem hohlraum innerhalb des organismus eines lebewesens
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
AU754952B2 (en) 1998-06-24 2002-11-28 Illumina, Inc. Decoding of array sensors with microspheres
US6470220B1 (en) * 1999-03-29 2002-10-22 The Regents Of The University Of California Diagnosis and treatment of cancers using in vivo magnetic domains
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US6544732B1 (en) * 1999-05-20 2003-04-08 Illumina, Inc. Encoding and decoding of array sensors utilizing nanocrystals
WO2001037721A2 (en) * 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
DE60035127T2 (de) * 2000-03-06 2008-02-14 Dade Behring Marburg Gmbh Mit polysacchariden beschichtete träger, deren herstellung und verwendung
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
AU2001266272B2 (en) * 2000-05-03 2005-09-15 Medigene Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US20050013775A1 (en) * 2000-06-01 2005-01-20 Kotov Nicholas A. Bioconjugates of nanoparticles as radiopharmaceuticals
EP1286705A2 (en) * 2000-06-01 2003-03-05 The Board Of Regents Of Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
US6690962B2 (en) * 2000-09-15 2004-02-10 Institut fur Diagnostikforshung GmbH Process for graphic visualization and diagnosis of thrombi by means of nuclear spin tomography with use of particulate contrast media
EP1368065B1 (de) * 2001-03-08 2007-06-27 Centrum für Angewandte Nanotechnologie (CAN) GmbH Paramagnetische nanopartikel
US7081489B2 (en) * 2001-08-09 2006-07-25 Florida State University Research Foundation Polymeric encapsulation of nanoparticles
DE10154016B4 (de) * 2001-10-26 2004-02-12 Berlin Heart Ag Magnetflüssigkeit und Verfahren zur ihrer Herstellung
EP1482956A1 (en) * 2002-02-01 2004-12-08 Vanderbilt University Targeted drug delivery methods
US20030185757A1 (en) * 2002-03-27 2003-10-02 Mayk Kresse Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
US20030190475A1 (en) * 2002-04-09 2003-10-09 Everett Carpenter Magnetic nanoparticles having passivated metallic cores
US6962685B2 (en) 2002-04-17 2005-11-08 International Business Machines Corporation Synthesis of magnetite nanoparticles and the process of forming Fe-based nanomaterials
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040096089A1 (en) * 2002-08-16 2004-05-20 David Borsook Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US20040058457A1 (en) * 2002-08-29 2004-03-25 Xueying Huang Functionalized nanoparticles
US20050064508A1 (en) 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
US6989196B2 (en) * 2002-10-02 2006-01-24 Florida State University Research Foundation Microencapsulation of magnetic material using heat stabilization
US7459145B2 (en) * 2002-10-25 2008-12-02 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
GB0227738D0 (en) * 2002-11-28 2003-01-08 Univ Liverpool Nanoparticle conjugates and method of production thereof
AU2003900335A0 (en) * 2003-01-22 2003-02-13 Sirtex Medical Limited Microparticles for selectively targeted hyperthermia
DE10331439B3 (de) * 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
US7235228B2 (en) * 2003-04-15 2007-06-26 The United States Of America As Represented By The Secretary Of The Navy Fluorescent-magnetic nanoparticles with core-shell structure
WO2004097417A1 (en) * 2003-05-02 2004-11-11 Canon Kabushiki Kaisha Structured construct and producing method therefor
KR100936269B1 (ko) * 2003-06-07 2010-01-12 연세대학교 산학협력단 자성체-고분자 입자 및 그의 제조방법
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
US8651113B2 (en) * 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7723311B2 (en) * 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
WO2005002643A2 (en) * 2003-06-24 2005-01-13 Johns Hopkins University Method and products for delivering biological molecules to cells using multicomponent nanostructures
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
GB0316912D0 (en) 2003-07-18 2003-08-20 Oxford Instr Superconductivity Therapeutic treatment
US20050031544A1 (en) * 2003-08-07 2005-02-10 Njemanze Philip Chidi Receptor mediated nanoscale copolymer assemblies for diagnostic imaging and therapeutic management of hyperlipidemia and infectious diseases
EP1673399B1 (en) * 2003-08-11 2017-04-05 Monogram BioSciences, Inc. Detecting and profiling molecular complexes
DE10354361A1 (de) * 2003-11-20 2005-06-23 Eberhard-Karls-Universität Tübingen Vorrichtung zum Einbringen in mittels Kernspinresonanztomografie untersuchbares Körpergewebe
WO2005060610A2 (en) * 2003-12-11 2005-07-07 The Trustees Of Columbia University In The City Ofnew York Nano-sized particles, processes of making, compositions and uses thereof
JP2007528784A (ja) * 2004-02-11 2007-10-18 マサチューセッツ・インスティチュート・オブ・テクノロジー 多層ポリマー被覆磁性ナノクラスタ
US8562505B2 (en) 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
DE102004010387A1 (de) * 2004-03-03 2005-09-22 Siemens Ag Kontrastmittel für die Röntgen-Computertomographie
JP2005296942A (ja) * 2004-03-15 2005-10-27 Hitachi Maxell Ltd 磁性複合粒子およびその製造方法
WO2005087367A1 (ja) * 2004-03-15 2005-09-22 Hitachi Maxell, Ltd. 磁性複合粒子およびその製造方法
US7842281B2 (en) * 2004-05-10 2010-11-30 The Florida State University Research Foundation Magnetic particle composition for therapeutic hyperthermia
DE102004052533A1 (de) * 2004-10-15 2006-05-04 Mykhaylyk, Olga, Dr. Magnetische Partikel zur Verwendung in Therapie und Diagnostik
CA2587085C (en) 2004-10-27 2017-08-08 Cepheid Closed-system multi-stage nucleic acid amplification reactions
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US20060140867A1 (en) * 2004-12-28 2006-06-29 Helfer Jeffrey L Coated stent assembly and coating materials
DE102005016873A1 (de) 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
WO2006113668A1 (en) * 2005-04-15 2006-10-26 University Of South Florida A method of transdermal drug delivery using hyaluronic acid nanoparticles
EP1721603A1 (en) * 2005-05-11 2006-11-15 Albert-Ludwigs-Universität Freiburg Nanoparticles for bioconjugation
WO2006125452A1 (en) * 2005-05-23 2006-11-30 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
US20060281104A1 (en) * 2005-06-13 2006-12-14 Macevicz Stephen C Leuco dye particles and uses thereof
WO2007002732A1 (en) * 2005-06-28 2007-01-04 Joslin Diabetes Center, Inc. Methods of imaging inflammation in pancreatic islets
US20070009436A1 (en) * 2005-07-08 2007-01-11 Rondinone Adam J Radionuclide nanoparticles encased by inorganic shell having vector biomolecules attached thereto
ATE522151T1 (de) * 2005-07-15 2011-09-15 Unilever Nv Eisen verstärktes lebensmittel und zusatzstoff
CZ301067B6 (cs) * 2006-02-24 2009-10-29 Ústav makromolekulární chemie AV CR Superparamagnetické nanocástice na bázi oxidu železa s modifikovaným povrchem, zpusob jejich prípravy a použití
EP2010089A4 (en) * 2006-04-21 2010-09-01 Philadelphia Children Hospital METHOD FOR TARGETING AND ISOLATING MAGNETIC GRADIENT THERAPEUTIC PREPARATIONS AND CORRESPONDING THERAPEUTIC SYSTEMS
WO2007133801A2 (en) * 2006-05-15 2007-11-22 Dmitri B Kirpotin Magnetic microparticles comprising organic substances
US8119352B2 (en) * 2006-06-20 2012-02-21 Cepheld Multi-stage amplification reactions by control of sequence replication times
US20080014285A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
US20090297626A1 (en) * 2006-11-03 2009-12-03 The Trustees Of Columbia University In The City Of New York Methods for preparing metal oxides
RU2481125C2 (ru) * 2006-12-18 2013-05-10 Колороббия Италия С.П.А. Магнитные наночастицы для применения при гипертермии, их приготовление и применение в магнитных системах для фармакологического использования
CA2743022C (en) 2007-01-21 2012-10-09 Hemoteq Ag Methods for coating catheter balloons with a defined quantity of active agent
US20080255425A1 (en) * 2007-04-13 2008-10-16 Ethicon Endo-Surgery, Inc. Nanoparticle treated medical devices
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
AU2008278605A1 (en) * 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
EP2022508A1 (en) * 2007-08-07 2009-02-11 Charité-Universitätsmedizin Berlin Production of targeted MRI probes by biocompatible coupling of macromolecules with charged nanoparticles
WO2009031859A2 (en) * 2007-09-06 2009-03-12 Anygen Co., Ltd. Multi-functional complex for imaging and drug delivery
EP2211910B1 (en) * 2007-11-07 2017-11-01 University Of Houston Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof
US20090157069A1 (en) * 2007-12-06 2009-06-18 Curtis Tom Systems and methods for thermal treatment of body tissue
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
JP2009256286A (ja) * 2008-04-21 2009-11-05 Fujifilm Corp 常磁性金属化合物含有ポリマー粒子
US20100018674A1 (en) * 2008-07-22 2010-01-28 Donald John Enzinna Reservoir with moveable partition for quick recovery
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
US20120107229A1 (en) * 2009-04-15 2012-05-03 Xuefei Huang Novel nano-probes for molecular imaging and targeted therapy of diseases
US8383025B2 (en) * 2009-05-19 2013-02-26 Nanyang Technological University Method of manufacturing micro patterned device and device obtained by the method
JP2012532670A (ja) 2009-07-10 2012-12-20 ボストン サイエンティフィック サイムド，インコーポレイテッド 薬剤搬送バルーンのためのナノ結晶の使用
EP2962707B1 (en) * 2009-07-17 2019-07-24 Boston Scientific Scimed, Inc. Drug delivery balloons with improved crystal size and density
US20110054236A1 (en) * 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
ES2600229T3 (es) * 2009-11-12 2017-02-07 Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH Nanopartículas magnéticas biocompatibles para el tratamiento de glioblastomas
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
WO2011081712A1 (en) * 2009-12-31 2011-07-07 Boston Scientific Scimed, Inc. Cryo activated drug delivery and cutting balloons
KR101057484B1 (ko) * 2010-03-19 2011-08-17 강원대학교산학협력단 소장의 조영을 위한 경구용 조영제
EP2611476B1 (en) 2010-09-02 2016-08-10 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US10398668B2 (en) 2010-10-19 2019-09-03 The Board Of Regents Of The University Of Oklahoma Glutamate treatment of cardiovascular disorders
US8740872B2 (en) 2010-10-19 2014-06-03 The Board Of Regents Of The University Of Oklahoma Magnetically-targeted treatment for cardiac disorders
US9744235B2 (en) 2010-10-19 2017-08-29 The Board Of Regents Of The University Of Oklahoma Treatment of cardiovascular disorders with targeted nanoparticles
KR101297815B1 (ko) 2010-11-18 2013-09-03 충남대학교산학협력단 폴리감마글루탐산과 광학영상다이의 복합체를 함유하는 센티넬 림프노드 감지용 광학영상 프로브
US8197471B1 (en) * 2011-02-14 2012-06-12 Samuel Harry Tersigni Core-excited nanoparticles and methods of their use in the diagnosis and treatment of disease
WO2012110835A2 (en) 2011-02-15 2012-08-23 Semmelweis Egyetem Prussian blue based nanoparticle as multimodal imaging contrast material
KR101398214B1 (ko) * 2011-04-06 2014-05-23 주식회사 바이오리더스 음이온성 고분자와 양이온성 고분자 이온복합체 기반 고감도 자기공명영상 나노조영제 및 이의 제조방법
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
WO2013022458A1 (en) 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
AU2011381641B2 (en) 2011-11-21 2015-04-23 Innotherapy Inc. Hydrogel comprising catechol group-coupled chitosan or polyamine and poloxamer comprising thiol group coupled to end thereof, preparation method thereof, and hemostat using same
EP2647389A1 (en) 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use
US8873041B1 (en) 2013-01-29 2014-10-28 Bayspec, Inc. Raman spectroscopy using multiple excitation wavelengths
US9987616B2 (en) 2013-02-27 2018-06-05 Empire Technology Development Llc Preparation and use of magnetic polymer nanocomposites
EP2823858A1 (en) * 2013-07-12 2015-01-14 Brossel, Rémy System generating a constraint field, and medical device implementing the same
US20150064107A1 (en) * 2013-09-04 2015-03-05 King's College London Imaging agent
DE102014106603A1 (de) 2014-05-12 2015-11-12 Verein zur Förderung von Innovationen durch Forschung, Entwicklung und Technologietransfer e.V. (Verein INNOVENT e.V.) Verfahren und Vorrichtung zur Abreicherung von zirkulierenden Tumorzellen aus einer Zellsuspension
US10059621B2 (en) * 2016-05-27 2018-08-28 Corning Incorporated Magnetizable glass ceramic composition and methods thereof
US20170342383A1 (en) 2016-05-27 2017-11-30 Corning Incorporated Lithium disilicate glass-ceramic compositions and methods thereof
CN111405913A (zh) 2017-11-28 2020-07-10 康宁股份有限公司 生物活性玻璃组合物和牙本质超敏性修复
WO2019108571A1 (en) 2017-11-28 2019-06-06 Corning Incorporated Chemically strengthened bioactive glass-ceramics
WO2019108558A1 (en) 2017-11-28 2019-06-06 Corning Incorporated High liquidus viscosity bioactive glass
WO2020174476A1 (en) * 2019-02-28 2020-09-03 Hadasit Medical Research Services And Development Ltd. Targeted magnetic vehicles and method of using the same
CN111330023B (zh) * 2020-03-23 2023-01-31 中国科学院宁波材料技术与工程研究所慈溪生物医学工程研究所 一种磁性纳米复合材料及其制备方法与应用
DE102020116859A1 (de) 2020-06-26 2021-12-30 Pharma Development Holding Gmbh Liposomen
CN112402389A (zh) * 2020-11-24 2021-02-26 常州欧法玛制药技术有限公司 一种唑吡坦双层渗透泵控释片及其制备方法
CN112870387B (zh) * 2021-02-26 2023-08-29 中山大学孙逸仙纪念医院 一种磁性纳米药物载体及其制备方法和应用
WO2023245000A2 (en) * 2022-06-13 2023-12-21 Russell Van De Casteele Methods for processing, enrichment, delivery, formulation, uptake and testing for supplements and pharmaceuticals

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5913521B2 (ja) * 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4323056A (en) * 1980-05-19 1982-04-06 Corning Glass Works Radio frequency induced hyperthermia for tumor therapy
US4501726A (en) * 1981-11-12 1985-02-26 Schroeder Ulf Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
SE8201972L (sv) * 1982-03-29 1983-09-30 Gambro Lundia Ab Magnetiskt paverkbara kristalliserade kolhydrat sferer eller partiklar att anvendas tillsammans med bioadsorberande material
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
JPS59195161A (ja) * 1983-04-21 1984-11-06 Fujirebio Inc 磁性粒子及びその製造法
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
US5720939A (en) * 1985-08-15 1998-02-24 Nycomed Imaging As Method of contrast enhanced magnetic resonance imaging using magnetically responsive-particles
US4788281A (en) * 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
JPS60260463A (ja) * 1984-06-01 1985-12-23 松下電器産業株式会社 高密度酸化物焼結体の製造方法
SE454885B (sv) * 1984-10-19 1988-06-06 Exploaterings Ab Tbf Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav
EP0184899B1 (en) * 1984-11-01 1990-04-18 Nycomed As Paramagnetic contrast agents for use in "in vivo" diagnostic methods using nmr, and their preparation
AU605461B2 (en) * 1986-04-07 1991-01-17 Francois Dietlin New compositions usable in tomo-densitometry
US5679323A (en) * 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US5352432A (en) * 1986-07-03 1994-10-04 Advanced Magnetics, Inc. Hepatocyte specific composition and their use as diagnostic imaging agents
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
DE3729697A1 (de) * 1987-09-04 1989-03-23 Siemens Ag Verfahren zur herstellung von pressfaehigem granulat fuer die fertigung von oxidkeramischen produkten, insbesondere mangan-zink-ferriten
US5395688A (en) * 1987-10-26 1995-03-07 Baxter Diagnostics Inc. Magnetically responsive fluorescent polymer particles
EP0381742B1 (en) * 1988-08-04 1996-06-19 Advanced Magnetics Incorporated Receptor mediated endocytosis type mri contrast agents
JPH0678247B2 (ja) * 1988-10-04 1994-10-05 大塚製薬株式会社 Ｎｍｒ造影用鉄含有製剤
US5612019A (en) * 1988-12-19 1997-03-18 Gordon, Deceased; David Diagnosis and treatment of HIV viral infection using magnetic metal transferrin particles
US5393525A (en) * 1989-07-21 1995-02-28 Nycomed Imaging As Contrast medium comprising superparamagnetic or ferromagnetic particles capable of increasing viscosity after administration
JP2726520B2 (ja) * 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体
US5389377A (en) * 1989-12-22 1995-02-14 Molecular Bioquest, Inc. Solid care therapeutic compositions and methods for making same
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
IL98744A0 (en) * 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
CA2078679C (en) * 1991-01-19 2006-12-05 Kyoji Kito Magnetic metal oxide ultrafine particles-containing composition
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
DK0543020T3 (da) * 1991-06-11 1998-08-31 Oxideret sammensætning indeholdende vandopløseligtcarboxypolysaccharid og magnetisk jernoxid
JP3189154B2 (ja) * 1991-07-18 2001-07-16 東ソー株式会社 免疫測定用担体の製造方法
JPH08500700A (ja) * 1992-06-08 1996-01-23 バイオクエスト インコーポレイテッド 分離、磁気分子スイッチ、および医療用途の無機リポソームとして使用する粒径を制御した無機粒子の製造
ES2130406T5 (es) * 1992-08-05 2003-12-16 Meito Sangyo Kk Material compuesto de pequeño diametro compuesto de carboxipolisacarido soluble en agua y oxido de hierro magnetico.
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
DE4301871A1 (de) * 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
EP0634174A1 (en) * 1993-07-13 1995-01-18 Takeda Chemical Industries, Ltd. Antianemic composition for veterinary use
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100806669B1 (ko) * 2005-06-23 2008-02-26 김정환 나노 입자-생체 복합체
KR100827292B1 (ko) * 2006-05-30 2008-05-07 애니젠 주식회사 실리콘-포함 수용성 고분자로 코팅된 나노입자 및 그의조영제로서의 용도
KR100809402B1 (ko) * 2007-01-29 2008-03-05 김정환 나노 입자 표지, 나노 입자 표지를 이용하는 진단 키트, 및진단 방법

Also Published As

Publication number Publication date
KR100278513B1 (ko) 2001-01-15
US20020141943A1 (en) 2002-10-03
DE4428851C2 (de) 2000-05-04
IL114713A (en) 2000-02-17
AU2921095A (en) 1996-03-04
US6576221B1 (en) 2003-06-10
NO970468L (no) 1997-04-02
EP0773796A1 (de) 1997-05-21
AU703042B2 (en) 1999-03-11
WO1996004017A1 (de) 1996-02-15
CN1103604C (zh) 2003-03-26
NO970468D0 (no) 1997-02-03
HUT77993A (hu) 1999-04-28
ZA956005B (en) 1996-02-22
CA2195318A1 (en) 1996-02-15
US6048515A (en) 2000-04-11
NO314785B1 (no) 2003-05-26
CN1155844A (zh) 1997-07-30
JPH10503496A (ja) 1998-03-31
CA2195318C (en) 2002-11-12
IL114713A0 (en) 1995-11-27
DE4428851A1 (de) 1996-02-08

Similar Documents

Publication Publication Date Title
KR970704476A (ko) 이중 코팅을 갖는 철-함유 나노입자 및 진단 및 치료에 있어서의 그의 용도(Ironcontaining nanoparticles with double coating and their use in diagnosis and therapy)
Abasian et al. Incorporation of magnetic NaX zeolite/DOX into the PLA/chitosan nanofibers for sustained release of doxorubicin against carcinoma cells death in vitro
Nezhadali et al. Synthesis of polypyrrole–chitosan magnetic nanocomposite for the removal of carbamazepine from wastewater: Adsorption isotherm and kinetic study
JP4619457B2 (ja) 徐放性製剤
CN1935277B (zh) 预防再狭窄的制剂
KR101854380B1 (ko) 본질적으로 자성인 하이드록시아파타이트
Lee et al. Efficient CD44-targeted magnetic resonance imaging (MRI) of breast cancer cells using hyaluronic acid (HA)-modified MnFe 2 O 4 nanocrystals
Yousefi et al. Synthesis and application of magnetic@ layered double hydroxide as an anti-inflammatory drugs nanocarrier
KR20010024836A (ko) 자기 반응성 조성물
EP1425306A2 (de) Nanopartikel mit daran immobilisiertem biologisch aktivem tnf
JP2005200426A (ja) 磁気標的化キャリア
Kuznetsov et al. Correlation of the coagulation rates and toxicity of biocompatible ferromagnetic microparticles
Parham et al. Synthesis of high generation thermo-sensitive dendrimers for extraction of rivaroxaban from human fluid and pharmaceutic samples
DE19624426A1 (de) Magnetische Flüssigkeiten für den Transport von diagnostisch oder therapeutisch wirksamen Substanzen
JPS60172923A (ja) シスジクロロジアンミン白金を含有する安定な注射液に適した水溶液
Christodoulou et al. Metal-organic frameworks for drug delivery: Degradation mechanism and in vivo fate
Wang et al. SiO2-coated layered gadolinium hydroxides for simultaneous drug delivery and magnetic resonance imaging
Muthu et al. Repurposing of antidepression drug sertraline for antimicrobial activity against Staphylococcus aureus: a potential approach for the treatment of osteomyelitis
Kermanian et al. A novel mesoporous superparamagnetic hybrid silica/hydroxyapatite nanocomposite as MRI contrast agent
Li et al. Novel magnetic nanocomposites combining selenium and iron oxide with excellent anti-biofilm properties
Egbaria et al. Adsorption of fluorescein dyes on albumin microspheres
CA2103556A1 (en) Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents, and processes for their preparation
RU2610170C1 (ru) Наноматериал для направленной доставки противоопухолевых препаратов и противоопухолевый препарат на его основе
Taavoni‐Gilan Chemical synthesis of MnFe2O4/chitosan nanocomposites for controlled release of ofloxacin drug
EP4169577A1 (de) 4-aminophenylphosphorylcholin-verbindungen zur blockade von c-reaktivem protein

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030919

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee